Abstract
In a double-blind clinical study, antidepressant plasma levels, parameters of platelet serotonin (5-HT) transport (Km, Vmax and basal platelet 5-HT content) and therapeutic response were measured in depressive patients treated with either paroxetine (30 mg/day) or amitriptyline (150 mg/day) for 6 weeks. No correlation could be found between paroxetine plasma levels and therapeutic outcome after 2, 4 and 6 weeks of treatment. In contrast to the amitriptyline group, a marked increase in Km from baseline to week 2 was determined in paroxetine-treated patients, with Km increase being correlated with paroxetine plasma levels at week 2. However, no significant relationship could be found between 5-HT transport parameters and any of the outcome measures in either treatment group.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
MeSH terms
-
Adult
-
Amitriptyline / pharmacokinetics
-
Amitriptyline / therapeutic use*
-
Antidepressive Agents / pharmacokinetics
-
Antidepressive Agents / therapeutic use*
-
Blood Platelets / drug effects*
-
Blood Platelets / metabolism
-
Depressive Disorder / blood
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / psychology
-
Double-Blind Method
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nortriptyline / pharmacokinetics
-
Paroxetine
-
Piperidines / pharmacokinetics
-
Piperidines / therapeutic use*
-
Psychiatric Status Rating Scales
-
Receptors, Serotonin / drug effects
-
Receptors, Serotonin / physiology
-
Serotonin / blood*
-
Serotonin Antagonists / pharmacokinetics
-
Serotonin Antagonists / therapeutic use*
Substances
-
Antidepressive Agents
-
Piperidines
-
Receptors, Serotonin
-
Serotonin Antagonists
-
Amitriptyline
-
Serotonin
-
Paroxetine
-
Nortriptyline